Sign inCreate account

Report workspace tools

NCT06634589RECRUITINGanonymous

A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies

Sponsor

Source record

BeOne Medicines

Phase

Source record

PHASE1

Modality

AI-normalized

small molecule

Target

AI-normalized

BGB-16673, Sonrotoclax, Zanubrutinib, Mosunetuzumab, Glofitamab, Obinutuzumab

Indication / condition

AI-normalized

B-cell Malignancy

Intervention

Source record

BGB-16673, Sonrotoclax, Zanubrutinib, Mosunetuzumab, Glofitamab, Obinutuzumab

Source & freshness

Source record

NCT ID

NCT06634589

Original source

ClinicalTrials.gov

Source last updated

Jun 03, 2026

Ingested at

Jun 05, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT06634589

Title

A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies

Sponsor

BeOne Medicines

Status

RECRUITING

Phase

PHASE1

Condition raw

B-cell Malignancy, Relapsed Cancer, Refractory Cancer, B-cell Lymphoma

Condition normalized

B-cell Malignancy, Relapsed Cancer, Refractory Cancer, B-cell Lymphoma

Modality raw

small molecule

Modality normalized

small molecule

Target raw

BGB-16673, Sonrotoclax, Zanubrutinib, Mosunetuzumab, Glofitamab, Obinutuzumab

Target normalized

BGB-16673, Sonrotoclax, Zanubrutinib, Mosunetuzumab, Glofitamab, Obinutuzumab

Interventions

BGB-16673, Sonrotoclax, Zanubrutinib, Mosunetuzumab, Glofitamab, Obinutuzumab

Public preview

Source record

The purpose of this study is to measure the safety, preliminary antitumor activity, pharmacokinetics, and pharmacodynamics with BGB-16673 in combination with other agents in participants with relapsed or refractory (R/R) B-cell malignancies. This study is structured as a master protocol with separate substudies. This study currently includes four substudies, and more substudies may be added as other combination agents are identified.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT06634589

Status

RECRUITING

Phase

PHASE1

Sponsor

BeOne Medicines

Executive brief

Investment-Ready Snapshot

The purpose of this study is to measure the safety, preliminary antitumor activity, pharmacokinetics, and pharmacodynamics with BGB-16673 in combination with other agents in participants with relapsed or refractory (R/R) B-cell malignancies. This study is structured as a master protocol with separate substudies. This study currently includes four substudies, and more substudies may be added as other combination agents are identified.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedJun 03, 2026
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT06634589

Indication

B-cell Malignancy

Modality

small molecule

Target

BGB-16673, Sonrotoclax, Zanubrutinib, Mosunetuzumab, Glofitamab, Obinutuzumab

Intervention

BGB-16673, Sonrotoclax, Zanubrutinib, Mosunetuzumab, Glofitamab, Obinutuzumab

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.